Home / Market News / $SGMT
benzinga Corporate Catalyst Impact 85/100 ● negative

Sagimet Biosciences shares are trading higher after the company announced 52-week results from the Phase 3 ASC40-304 OLE trial of denifanstat for acne. The company suspended its at-the-market sale through Leerink Partners and announced the pricing of its $115 million offering of 8,750,010 shares at $10.00 per share.

Sep 30, 2026, 1:07 PM UTC · Primary ticker $SGMT

Sagimet Biosciences shares are surging due to positive Phase 3 trial results for its acne treatment, denifanstat, which has led to a strategic shift in financing. The company suspended its ATM sale and announced a significant stock offering, indicating strong investor confidence and a clear path to funding future operations.

The positive 52-week results from the Phase 3 trial of denifanstat for acne are a major catalyst for Sagimet Biosciences, demonstrating the drug's efficacy and potential market viability. This success has enabled the company to secure substantial funding through a $115 million stock offering, which will support further development and commercialization efforts. The suspension of the at-the-market sale through Leerink Partners suggests a more favorable and structured financing approach. Key risks include the successful execution of the offering and future regulatory approvals. This event primarily impacts the biotechnology sector, particularly companies with drugs in late-stage clinical trials. Trading implications for SGMT are likely continued upward momentum in the short term, driven by investor optimism and improved financial stability.

$SGMT positive Positive Phase 3 trial results and successful stock offering
Source: benzinga
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only.